Search: onr:"swepub:oai:gup.ub.gu.se/157891" >
Orexin Receptor Ant...
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
-
Hoever, P. (author)
-
Dorffner, G. (author)
-
Benes, H. (author)
-
show more...
-
Penzel, T. (author)
-
Danker-Hopfe, H. (author)
-
Barbanoj, M. J. (author)
-
Pillar, G. (author)
-
Saletu, B. (author)
-
Polo, O. (author)
-
Kunz, D. (author)
-
Zeitlhofer, J. (author)
-
Berg, S. (author)
-
Partinen, M. (author)
-
Bassetti, C. L. (author)
-
Hogl, B. (author)
-
Ebrahim, I. O. (author)
-
Holsboer-Trachsler, E. (author)
-
Bengtsson, H. (author)
-
- Peker, Yüksel, 1961 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Hemmeter, U. M. (author)
-
Chiossi, E. (author)
-
Hajak, G. (author)
-
Dingemanse, J. (author)
-
show less...
-
(creator_code:org_t)
- 2012-05-02
- 2012
- English.
-
In: Clinical pharmacology and therapeutics. - : Springer Science and Business Media LLC. - 1532-6535 .- 0009-9236. ; 91:6, s. 975-985
- Related links:
-
https://ascpt.online...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1-week intervals. The primary end point was sleep efficiency (SE) measured by polysomnography; secondary end points were objective latency to persistent sleep (LPS), wake after sleep onset (WASO), safety, and tolerability. Dose-dependent almorexant effects were observed on SE, LPS, and WASO. SE improved significantly after almorexant 400 mg vs. placebo (mean treatment effect 14.4%; P < 0.001). LPS (-18 min (P = 0.02)) and WASO (-54 min (P < 0.001)) decreased significantly at 400 mg vs. placebo. Adverse-event incidence was dose-related. Almorexant consistently and dose-dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hoever, P.
-
Dorffner, G.
-
Benes, H.
-
Penzel, T.
-
Danker-Hopfe, H.
-
Barbanoj, M. J.
-
show more...
-
Pillar, G.
-
Saletu, B.
-
Polo, O.
-
Kunz, D.
-
Zeitlhofer, J.
-
Berg, S.
-
Partinen, M.
-
Bassetti, C. L.
-
Hogl, B.
-
Ebrahim, I. O.
-
Holsboer-Trachsl ...
-
Bengtsson, H.
-
Peker, Yüksel, 1 ...
-
Hemmeter, U. M.
-
Chiossi, E.
-
Hajak, G.
-
Dingemanse, J.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
Clinical pharmac ...
- By the university
-
University of Gothenburg